Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations, in Recurrent and Metastatic Microsatellite Instability High (MSI-H) and non-MSI-H Colon Cancer

Trial Profile

A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations, in Recurrent and Metastatic Microsatellite Instability High (MSI-H) and non-MSI-H Colon Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cobimetinib (Primary) ; Daratumumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Relatlimab (Primary)
  • Indications Colon cancer; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms CheckMate 142
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 04 Nov 2019 Planned End Date changed from 30 Dec 2020 to 6 Jul 2022.
    • 04 Nov 2019 Planned primary completion date changed from 3 Dec 2019 to 6 Jul 2022.
    • 29 Jul 2019 Planned number of patients changed from 340 to 375.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top